Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease

Molecular Neurobiology

Volumn 53, Issue 5, 2016, Pages 3227-3234

  Borreca, Antonella ^a   Gironi, Katia ^b   Amadoro, Giusy ^c,d   Ammassari Teule, Martine ^a,e  

^a CNR   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^d EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Alzheimer disease; APP; FMRP; hnRNP C; RNA binding protein; SAD; Translational control

Indexed keywords

AMYLOID PRECURSOR PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN GROUP C; MESSENGER RNA; MUTANT PROTEIN; TISSUE EXTRACT;

AGE; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN SYNAPTOSOME; DISEASE ASSOCIATION; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; TG2576 MOUSE; ANIMAL; C57BL MOUSE; FEMALE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN SYNTHESIS; SYNAPSE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP C; HIPPOCAMPUS; HUMANS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTANT PROTEINS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SYNAPSES; TISSUE EXTRACTS; TRANSCRIPTION, GENETIC;

EID: 84930526848     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9229-8     Document Type: Article

References (31)

1. Stancu IC, Ris L, Vasconcelos B, Marinangeli C, Goeminne L, Laporte V et al (2014) Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer’s disease. FASEB J 28(6):2620–2631. doi:10.1096/fj.13-246702
2. Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron 82(4):756–771. doi:10.1016/j.neuron.2014.05.004, Review
3. Ding Y, Ko MH, Pehar M, Kotch F, Peters NR, Luo Y et al (2012) Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces β-secretase (BACE1) levels and Aβ generation. J Biol Chem 287(11):8424–8433. doi:10.1074/jbc.M111.310136
4. Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K et al (2008) In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 324(3):957–969
5. Sadleir KR, Eimer WA, Cole SL (2015) Vassar R Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener 10(1):1. doi:10.1186/1750-1326-10-1
6. Schafer MJ, Alldred MJ, Lee SH, Calhoun ME, Petkova E, Mathews PM et al (2014) Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2014.10.043
7. Strömberg K, Eketjäll S, Georgievska B, Tunblad K, Eliason K, Olsson F et al (2015) Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production. FEBS J 282(1):65–73. doi:10.1111/febs.13103
8. Fernandez MA, Klutkowski JA, Freret T, Wolfe MS (2014) Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid β-peptides (Aβ) by γ-secretase to increase 42-to-40-residue Aβ. J Biol Chem 289(45):31043–31052. doi:10.1074/jbc.M114.581165
9. Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B et al (2014) Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APP London mice. J Neurosci 34(35):11621–11630. doi:10.1523/JNEUROSCI.1405-14.2014
10. Subaiea GM, Ahmed AH, Adwan LI, Zawia NH (2015) Reduction of amyloid-β deposition and attenuation of memory deficits by tolfenamic acid. J Alzheimers Dis 43(2):425–433. doi:10.3233/JAD-132726
11. Vignini A, Morganti S, Salvolini E, Sartini D, Luzzi S, Fiorini R et al (2013) Amyloid precursor protein expression is enhanced in human platelets from subjects with Alzheimer’s disease and Frontotemporal lobar degeneration: a real-time PCR study. Exp Gerontol. doi:10.1016/j.exger.2013.10.008
12. Johnston JA, Cowburn RF, Norgren S, Wiehager B, Venizelos N, Winblad B et al (1994) Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer’s disease APP670/671 mutation. FEBS Lett 354(3):274–278
13. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP et al (2007) Expression of APP pathway mRNAs and proteins in Alzheimer’s disease. Brain Res 1161:116–123
14. Lee EK, Kim HH, Kuwano Y, Abdelmohsen K, Srikantan S, Subaran SS et al (2010) hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat Struct Mol Biol 17(6):732–739. doi:10.1038/nsmb.1815
15. Westmark CJ, Malter JS (2012) The regulation of AβPP expression by RNA-binding proteins. Ageing Res Rev 11(4):450–459. doi:10.1016/j.arr.2012.03.005
16. Ruberti F, Barbato C, Cogoni C (2010) Post-transcriptional regulation of amyloid precursor protein by microRNAs and RNA binding proteins. Commun Integr Biol 3(6):499–503. doi:10.4161/cib.3.6.13172
17. Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U (2001) Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 10(4):329–338
18. Westmark CJ, Malter JS (2007) FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 5(3):e52
19. Rajagopalan LE, Westmark CJ, Jarzembowski JA, Malter JS (1998) hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA. Nucleic Acids Res 26(14):3418–3423
20. Zaidi SH, Malter JS (1995) Nucleolin and heterogeneous nuclear ribonucleoprotein C proteins specifically interact with the 3′-untranslated region of amyloid protein precursor mRNA. J Biol Chem 270(29):17292–17298
21. Renoux AJ, Carducci NM, Ahmady AA, Todd PK (2014) Fragile X mental retardation protein expression in Alzheimer’s disease. Front Genet 5:360. doi:10.3389/fgene.2014.00360. eCollection 2014
22. Hamilton A, Esseltine JL, DeVries RA, Cregan SP, Ferguson SS (2014) Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer’s disease. Mol Brain 7:40. doi:10.1186/1756-6606-7-40
23. Westmark CJ, Westmark PR, O’Riordan KJ, Ray BC, Hervey CM, Salamat MS et al (2011) Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. PLoS One 6(10):e26549. doi:10.1371/journal.pone.0026549
24. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R et al (1989) Amyloid A4 protein and its precursor in Down’s syndrome and Alzheimer’s disease. N Engl J Med 320(22):1446–1452
25. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A et al (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38(1):24–26
26. Brouwers N, Sleegers K, Engelborghs S, Bogaerts V, Serneels S, Kamali K et al (2006) Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer’s disease. Brain 129(Pt 11):2984–2991
27. Long JM, Ray B, Lahiri DK (2012) MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 287(37):31298–31310. doi:10.1074/jbc.M112.366336
28. Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q et al (2014) Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzeimer’s disease. J Neurosci 34(11):3826–3840. doi:10.1523/JNEUROSCI.5171-13.2014
29. Westmark CJ, Westmark PR, Beard AM, Hildebrandt SM, Malter JS (2008) Seizure susceptibility and mortality in mice that over-express amyloid precursorprotein. Int J Clin Exp Pathol 1(2):157–168
30. Amatniek JC, Hauser WA, Del Castillo-Castaneda C, Jacobs DM, Marder K, Bell K et al (2006) Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 47(5):867–872
31. Asuni AA, Guridi M, Pankiewicz JE, Sanchez S, Sadowski MJ (2014) Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. Ann Neurol 75(5):684–699. doi:10.1002/ana.24149